Efficacy Study of Oxygenated Glycerol Triesters to Treat Xerostomia

NCT ID: NCT00332618

Last Updated: 2006-06-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-09-30

Study Completion Date

2004-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the trial was to evaluate the efficacy and clinical safety and acceptability of Oxygenated Glycerol Triesters in the relief of symptoms of xerostomia versus a reference comparator.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Xerostomia is due to inadequate (hyposialia) or inexistent (asialia) saliva secretion.

There are may causes. Transitory xerostomia may occur in the presence of anxiety (stage fright, fear or dehydration). Prolonged xerostomia is most often related to a systemic disease, certain medicines or to radiotherapy of the head or neck.

Salivation depends upon the autonomic (sympathetic and parasympathetic) nervous system for its production and on the central nervous system for stimuli-dependant excretion. Substances acting on alpha an beta sympathetic receptors, whether agonists or antagonists, may induce hyposialia. Atropine, the main antagonist of the parasympathetic system, is present in many medicines used for pulmonary, ophthalmic or neurological purposes, potentially causing hyposialia. Similarly, imipramine antidepressants, phenothiazine neuroleptics, antihistamines and disopyramide predispose to the onset of hyposialia.

Xerostomia is often accompanied by buccal signs such as impaired sense of taste, halitosis and buccal ulcers and interferes with functions such as speech, chewing and swallowing. Because of reduced salivary secretion , there is a disturbance of the microbial colonization of the buccal cavity. Xerostomia has significant untoward effects on the buccal cavity and the quality of life of patients.

The basis of the treatment of xerostomia involves the use of saliva substitutes and/or saliva stimulants. Oxygenated Glycerol Triesters is neither a replacement for nor stimulant of saliva. It is a lubricant and protective solution for endobuccal spray.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Xerostomia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

DEFINED_POPULATION

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OXYGENATED GLYCEROL TRIESTERS

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* men or women over 18 years of age
* with a diagnosis requiring the prescription of psychotropies (antidepressants, tranquilizers, etc) for more than 6 weeks
* having received no palliative treatment for xerostomia for a minimum of the past 2 weeks
* having xerostomia meeting the questionnaire selection criteria and the sialometer method parameters
* patients legally competent to give their consent
* capable of and accepting to participate in the trial and capable of and accepting to answer trial questionnaires

Exclusion Criteria

* combined treatments incompatible with the trial, un particular alcoholic solutions
* diabetes, any buccal condition requiring antimicrobial treatment
* Sjögren's syndrome or othermedical causes of xerostomia
* current participation in other clinical trials
* patient suffering from cancer
* patients with allergy to or known intolerance of any of the constituents of the investigational products
* patients treated with pilocarpine
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratoires CARILENE

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

YVES YT TILLET, Expertpharma

Role: STUDY_DIRECTOR

WHITE TILLET Consultants

Jean Baptiste JO Orler, Psychiatrist

Role: PRINCIPAL_INVESTIGATOR

CHU HOPITAL DES BROUSSAILLES

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Hopital Des Broussailles

Cannes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Fox PC. Management of dry mouth. Dent Clin North Am. 1997 Oct;41(4):863-75.

Reference Type BACKGROUND
PMID: 9344281 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Laboratoires CARILENE

Identifier Type: -

Identifier Source: org_study_id